Are you Dr. Dolan?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 31 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
800 Sw 13th Ave
Portland, OR 97205Phone+1 503-221-0161Fax+1 503-274-1697
Summary
- Dr. Philip Dolan, MD is a gastroenterologist in Portland, Oregon. He is currently licensed to practice medicine in Oregon. He is affiliated with Legacy Good Samaritan Medical Center, Legacy Emanuel Medical Center, and Providence St. Vincent Medical Center.
Education & Training
Louisiana State University School of MedicineResidency, Internal Medicine, 1973 - 1977- Louisiana State University School of Medicine in New OrleansClass of 1973
Certifications & Licensure
OR State Medical License 2005 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Publications & Presentations
PubMed
- 108 citationsTruncated tau and Aβ cooperatively impair mitochondria in primary neuronsRodrigo A. Quintanilla, Philip J. Dolan, Youngnam N. Jin, Gail V.W. Johnson
Neurobiology of Aging. 2012-03-01 - 136 citationsCaspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease.Rodrigo A. Quintanilla, Tori A. Matthews-Roberson, Philip J. Dolan, Gail V.W. Johnson
The Journal of Biological Chemistry. 2009-07-10 - 259 citationsHistone deacetylase 6 interacts with the microtubule-associated protein tau.Huiping Ding, Philip J. Dolan, Gail V.W. Johnson
Journal of Neurochemistry. 2008-09-01
Press Mentions
IMIDomics, IgGenix and neuro42 Close Series A Rounds Worth MillionsJuly 28th, 2021- neuro42 Announces the Closing of $6.5M Series A RoundJuly 27th, 2021
